0
Signin
countryflagUS

18889881171

AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%

Arvinas Inc

Healthcare US ARVN

32.54USD
-1.46(4.29%)

Last update at 2024-04-24T20:00:00Z

Day Range

32.5133.83
LowHigh

52 Week Range

13.5742.38
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -251.00000M -191.00000M -119.33206M -70.29223M -41.48047M
Minority interest - - - - -
Net income -271.90000M -183.20000M -111.78671M -62.13204M -41.48047M
Selling general administrative 79.60M 61.60M 38.30M 27.31M 12.93M
Selling and marketing expenses - - - - -
Gross profit 131.40M 46.70M 21.80M 42.98M 14.32M
Reconciled depreciation 8.20M 6.00M 4.02M 2.25M 0.71M
Ebit -271.40000M -201.30000M -128.88198M -53.77742M -44.50808M
Ebitda -263.20000M -195.30000M -124.85748M -51.52451M -43.80208M
Depreciation and amortization 8.20M 6.00M 4.02M 2.25M 0.71M
Non operating income net other 1.60M 4.40M 5.59M -18.68214M 2.38M
Operating income -263.20000M -195.30000M -124.85748M -51.52451M -43.80208M
Other operating expenses 394.60M 242.00M 146.66M 94.50M 58.13M
Interest expense 12.00M 0.10M 0.07M 0.09M 0.06M
Tax provision 20.90M - - - -
Interest income 12.20M 1.90M 3.59M 4.56M 2.47M
Net interest income 12.20M 1.80M 3.52M 4.47M 2.41M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 20.90M -7.80000M -7.54536M -8.16019M 2.38M
Total revenue 131.40M 46.70M 21.80M 42.98M 14.32M
Total operating expenses 394.60M 242.00M 146.66M 94.50M 58.13M
Cost of revenue - - - - 0.00000M
Total other income expense net 12.20M 4.30M 5.53M -18.76771M -0.09105M
Discontinued operations - - - - -
Net income from continuing ops -282.50000M -191.00000M -119.33206M -70.29223M -41.48047M
Net income applicable to common shares -282.50000M -191.00000M -119.33206M -70.29223M -239.84722M
Preferred stock and other adjustments - - - - 198.37M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1268.80M 1581.60M 717.37M 301.64M 199.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 21.40M 19.70M 6.11M 3.73M 2.82M
Total liab 703.90M 799.90M 75.11M 74.96M 62.61M
Total stockholder equity 564.90M 781.70M 642.26M 226.69M 136.67M
Deferred long term liab - - - - -
Other current liab 69.00M 23.10M 18.86M 7.60M 4.00M
Common stock 0.10M - 0.05M 0.04M 0.03M
Capital stock 0.10M 0.00000M 0.05M 0.04M 0.03M
Retained earnings -965.40000M -682.90000M -491.88891M -372.55685M -302.26462M
Other liab 405.10M 534.30M 22.94M 38.43M 37.63M
Good will - - - - -
Other assets 10.80M 0.10M 0.03M 0.03M 0.02M
Cash 81.30M 108.30M 588.37M 9.21M 3.19M
Cash and equivalents - - - - -
Total current liabilities 295.10M 261.70M 49.09M 32.81M 22.98M
Current deferred revenue 218.60M 206.20M 22.15M 19.98M 16.07M
Net debt -75.80000M -103.30000M -584.33297M -4.82305M -1.03560M
Short term debt 1.80M 1.10M 0.95M 0.67M 0.15M
Short long term debt - - - - 0.15M
Short long term debt total 5.50M 5.00M 4.04M 4.39M 2.15M
Other stockholder equity 1549.40M 1469.20M 1133.54M 599.10M 439.12M
Property plant equipment 13.40M 16.60M 12.26M 10.73M 3.58M
Total current assets 1240.20M 1552.50M 703.09M 290.88M 195.68M
Long term investments - - - - -
Net tangible assets 564.90M 781.70M 642.26M 226.69M 136.67M
Short term investments 1124.00M 1394.30M 100.16M 271.66M 184.64M
Net receivables 8.00M 25.70M 8.44M 6.28M 5.03M
Long term debt 1.00M 1.00M 2.00M 2.00M 2.00M
Inventory 5.50M 4.50M - - -
Accounts payable 5.70M 31.30M 7.12M 4.56M 2.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -19.20000M -4.60000M 0.56M 0.11M -0.21772M
Additional paid in capital - - - - -
Common stock total equity 0.10M - 0.05M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity -965.40000M -682.90000M -491.88891M -372.55685M -302.26462M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.80M 12.50M 0.03M 0.03M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 28.60M 29.10M 14.28M 10.76M 3.60M
Capital lease obligations 4.50M 4.00M 2.04M 2.39M -
Long term debt total 1.00M 1.00M 2.00M 2.00M 2.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 249.60M -1308.90000M 170.70M -86.85254M -176.83470M
Change to liabilities 20.20M 719.20M 12.85M 5.21M 2.46M
Total cashflows from investing activities 242.80M -1313.60000M 164.25M -93.09656M -179.66536M
Net borrowings - - - -0.16961M 1.83M
Total cash from financing activities 4.70M 278.60M 504.67M 139.74M 168.06M
Change to operating activities - -26.90000M 6.34M -2.07020M -3.11156M
Net income -282.50000M -191.00000M -119.33206M -70.29223M -41.48047M
Change in cash -26.00000M -475.60000M 579.16M 6.02M -27.72234M
Begin period cash flow 112.80M 588.40M 9.21M 3.19M 30.91M
End period cash flow 86.80M 112.80M 588.37M 9.21M 3.19M
Total cash from operating activities -273.50000M 559.40M -89.75693M -40.62634M -16.11767M
Issuance of capital stock 0.00000M 264.60M 525.64M 137.69M 169.58M
Depreciation 8.20M 6.00M 4.02M 2.25M 0.71M
Other cashflows from investing activities - - - -86.85254M -176.83470M
Dividends paid - - - -3.42177M 60.50M
Change to inventory - -26.90000M 6.34M -2.07020M -3.26156M
Change to account receivables 14.00M -14.00000M -1.00000M 2.78M 22.22M
Sale purchase of stock 4.70M 14.00M -29.23483M -0.59713M -3.42359M
Other cashflows from financing activities 242.80M 14.00M 8.26M 6.25M 117.57M
Change to netincome 75.50M 65.70M 29.84M 20.07M 11.82M
Capital expenditures 6.80M 4.70M 6.45M 6.24M 2.83M
Change receivables 17.70M -17.30000M -2.16283M -1.24903M 21.01M
Cash flows other operating -116.40000M 668.30M -15.76795M 3.90M -10.89947M
Exchange rate changes - - - - -
Cash and cash equivalents changes -26.00000M -475.60000M 579.16M 6.02M -27.72234M
Change in working capital -82.60000M 678.30M -5.93968M 7.17M 12.57M
Stock based compensation 75.50M 57.10M 30.23M 20.07M 11.63M
Other non cash items 7.90M 9.80M 1.65M 0.17M 0.27M
Free cash flow -280.30000M 554.70M -96.20447M -46.87037M -18.94833M

Fundamentals

  • Previous Close 34.00
  • Market Cap2261.00M
  • Volume466072
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-306.50000M
  • Revenue TTM159.40M
  • Revenue Per Share TTM2.98
  • Gross Profit TTM 131.40M
  • Diluted EPS TTM-5.52

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARVN
Arvinas Inc		 -1.46 4.29% 32.54 - 17.70 12.58 4.39 6.35 -3.3204
NVO
Novo Nordisk A/S		 -2.48 1.93% 126.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.58 1.23% 126.80 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.15 1.02% 400.76 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.61 0.67% 90.10 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas Inc

5 Science Park, New Haven, CT, United States, 06511

Key Executives

Name Title Year Born
Dr. John G. Houston Ph.D. CEO, Pres & Director 1960
Mr. Sean A. Cassidy CPA, CPA, M.B.A. CFO & Treasurer 1970
Dr. Ian Taylor Ph.D. Chief Scientific Officer 1962
Dr. Ronald A. Peck Chief Medical Officer NA
Mr. Jeff Boyle VP of Investor Relations NA
Mr. Matthew Batters J.D. Gen. Counsel & Corp. Sec. 1975
Dr. Randy Teel Ph.D. Sr. VP of Corp. & Bus. Devel. 1979
Mr. Steve Weiss Sr. VP & Chief HR Officer 1970
Dr. John A. Grosso Ph.D. Sr. VP of R&D Technical Operations 1957
Ms. Angela M. Cacace Ph.D. Sr. VP of Neuroscience & Platform Biology 1968

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).